Navigation Links
A drug used to treat HIV might defuse deadly staph infections
Date:12/14/2012

A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hospitalizations each year. Their study is published online this week in Nature.

"What are the chances that a drug for HIV could possibly treat a virulent Staph infection?" asks Victor J. Torres, PhD, assistant professor of microbiology, and senior author of the study. "These findings are the result of a fantastic collaboration that we hope will result in significant clinical benefit." Staph causes toxic shock syndrome, pneumonia, and food poisoning, among other illnesses, and is becoming increasingly resistant to antibiotics.

The discovery arose from a serendipitous finding that was a part of a collaborative study between Dr. Torres, a bacteriologist, and immunologist Derya Unutmaz, MD, associate professor of microbiology and pathology and medicine, whose laboratories are adjacent to each other.

They focused on a receptor called CCR5 that dots the surface of immune T cells, macrophages, and dendritic cells. Sixteen years ago, researchers at NYU School of Medicine discovered that CCR5 is the receptor HIV uses to gain entry into T cells in order to replicate, spread, and cause an infection that can progress into AIDS.

That same receptor has now been found to be critical to the ability of certain strains of Staph to specifically target and kill cells with CCR5, which orchestrate an immune response against the bacteria. The scientists discovered that one of the toxins the bacterium releases, called LukED, latches on to CCR5 and subsequently punches holes through the membrane of immune cells, causing them to rapidly die. The LukED toxin belongs to a family of proteins called leukotoxins, encoded and produced by Staph to fight off the immune system's defenses.

This discovery was made
'/>"/>

Contact: Christopher Rucas
Christopher.Rucas@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Lethal stings from the Australian box jellyfish could be treated with zinc
2. Vaccine offers promise as post-surgery treatment for pancreatic cancer patients
3. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
4. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
5. ALS TDI and Gladstone Institutes collaborate to discover potential ALS treatments
6. Protein injection points to muscular dystrophy treatment
7. Possible new treatment for Ewing sarcoma
8. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
9. Notre Dame research could improve sustainability and cost effectiveness of wastewater treatment
10. Second most common infection in the US proving harder to treat with current antibiotics
11. Hormone combination effective and safe for treating obesity in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2015)... 2015  Lintec of America recently announced an exclusive ... (CNT) macrostructures, including sheets, yarns and ribbons, developed at ... Leveraging the vast industrial resources of the global Lintec ... Lintec of America is forming the Nano-Science and Technology ... focusing on scaling up the manufacturing and commercialization of ...
(Date:2/5/2015)... 26, 2015   Epic Sciences , a precision diagnostics ... that Murali Prahalad , Ph.D., president and CEO, is ... (PMWC) 2015: Silicon Valley, which is taking place at ... on January 26-28, 2015. Dr. ... as Biomarkers." Last year, Epic Sciences was a finalist in ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... its observed behavior and characteristics is well-established, ... is still lacking. There are also many lingering mysteries ... question of why sex is such a prevalent reproductive ... of Sciences; Jilin University in Jilin, China; and the ...
... have an overall positive impact on wild salmon populations ... of Southampton. Representatives of recreational fisheries interests north ... can harm economically important fish stocks due to their ... phases. However, results of a study conducted by ...
... Research at Bangor University has identified a switch in cells ... and other localized tumors can be effectively treated by a ... genes. Behind this novel therapy is the enigmatic ability of ... Although thermotherapy is now more widely used, the underlying principles ...
Cached Biology News:Physics and math shed new light on biology by mapping the landscape of evolution 2Do beavers benefit Scottish wild salmon? 2Do beavers benefit Scottish wild salmon? 3
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015  23andMe, the ... Kate Black as Privacy Officer and Corporate ... and state privacy laws as well as health care ... team, she will be responsible for reviewing, updating and ... in the U.S. and abroad. She joined the company ...
(Date:2/26/2015)... FT. LAUDERDALE, Fla. , Feb. 26, 2015 /PRNewswire/ ... discussed growth priorities driven by key research advancements ... Health segments at today,s Bank of America Merrill Lynch ... worldwide met the challenge of building grain supplies the ... expected to continue at the pace of the last ...
(Date:2/26/2015)... -- BioEnterprise today announced that Northeast Ohio ... billion in growth funding during the past 13 years.  ... state – including the Ohio Third Frontier - and ... been raised in the past five years. ... BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... (Nasdaq: GPRO ) announced today that the Company ... in San Francisco on January 10, 2011 at approximately 11:30 ... live and may be accessed through a link on the ... webcast will be available for 30 days following the event. ...
... Rx Communications Group, LLC will host a panel ... interviews with financial as well as trade journalists. The ... place in San Francisco on Tuesday, January 11, 2011 ... will focus on media interview preparation and understanding the ...
... NEOG ) announced today that its net income ... 30, increased 33% from the previous year,s second quarter. Net ... share, compared to the prior year,s $0.20. Second ... year,s $35,251,000. Year-to-date revenues for the first six months of ...
Cached Biology Technology:Gen-Probe to Webcast Presentation at the 29th Annual J.P. Morgan Healthcare Conference 2Rx Communications Group to Host Panel Discussion for Biotechnology Executives on Communicating with the Media 2Rx Communications Group to Host Panel Discussion for Biotechnology Executives on Communicating with the Media 3Neogen Reports 33% Increase in Net Income 2Neogen Reports 33% Increase in Net Income 3Neogen Reports 33% Increase in Net Income 4Neogen Reports 33% Increase in Net Income 5
... , Maintenance 112 days/each , ... Immunizations/Boost injections x5 /each , ... , Production bleed (25 ml blood =12 ml ... ml blood (~50 ml serum) x1 each , ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
Request Info...
Biology Products: